Do We Need Gadolinium-Based Contrast Agents for Routine MRI Surveillance of Unoperated Pituitary Macroadenoma?
Journal
AJNR. American journal of neuroradiology
ISSN: 1936-959X
Titre abrégé: AJNR Am J Neuroradiol
Pays: United States
ID NLM: 8003708
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
28
03
2022
accepted:
04
05
2022
pubmed:
24
6
2022
medline:
12
7
2022
entrez:
23
6
2022
Statut:
ppublish
Résumé
The use of gadolinium-based contrast agents contributes to the cost of MR imaging and prolongs image-acquisition time. There are also recent concerns regarding gadolinium deposition, particularly in patients who require frequent follow-up MRIs. The purpose of this study was to assess whether gadolinium-based contrast agents are needed during MR imaging follow-up for unoperated pituitary macroadenoma. A total of 105 patients with unoperated pituitary macroadenoma who underwent follow-up MR imaging of the sella were included in this retrospective study. The craniocaudal dimension, cavernous sinus invasion grading, and optic pathway compression were assessed independently on coronal T2WI and compared with coronal T1-weighted images with gadolinium-based contrast agents (T1 postcontrast images). The agreement between the T2WI and T1 postcontrast images for the craniocaudal dimension was assessed using the intraclass correlation coefficient; for the cavernous sinus invasion and optic pathway compression, it was assessed using κ statistics. There was excellent agreement for the craniocaudal dimensions between T2WI and T1 postcontrast images (intraclass correlation coefficient = 0.96, MR imaging of the sella without the use of gadolinium-based contrast agents could potentially be considered for the follow-up of unoperated pituitary macroadenomas. This choice can reduce the MR imaging examination cost and acquisition time and avoids potential adverse effects of gadolinium-based contrast agents.
Sections du résumé
BACKGROUND AND PURPOSE
The use of gadolinium-based contrast agents contributes to the cost of MR imaging and prolongs image-acquisition time. There are also recent concerns regarding gadolinium deposition, particularly in patients who require frequent follow-up MRIs. The purpose of this study was to assess whether gadolinium-based contrast agents are needed during MR imaging follow-up for unoperated pituitary macroadenoma.
MATERIALS AND METHODS
A total of 105 patients with unoperated pituitary macroadenoma who underwent follow-up MR imaging of the sella were included in this retrospective study. The craniocaudal dimension, cavernous sinus invasion grading, and optic pathway compression were assessed independently on coronal T2WI and compared with coronal T1-weighted images with gadolinium-based contrast agents (T1 postcontrast images). The agreement between the T2WI and T1 postcontrast images for the craniocaudal dimension was assessed using the intraclass correlation coefficient; for the cavernous sinus invasion and optic pathway compression, it was assessed using κ statistics.
RESULTS
There was excellent agreement for the craniocaudal dimensions between T2WI and T1 postcontrast images (intraclass correlation coefficient = 0.96,
CONCLUSIONS
MR imaging of the sella without the use of gadolinium-based contrast agents could potentially be considered for the follow-up of unoperated pituitary macroadenomas. This choice can reduce the MR imaging examination cost and acquisition time and avoids potential adverse effects of gadolinium-based contrast agents.
Identifiants
pubmed: 35738673
pii: ajnr.A7554
doi: 10.3174/ajnr.A7554
pmc: PMC9262062
doi:
Substances chimiques
Contrast Media
0
Gadolinium
AU0V1LM3JT
Gadolinium DTPA
K2I13DR72L
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1024-1028Informations de copyright
© 2022 by American Journal of Neuroradiology.
Références
Radiology. 2014 Mar;270(3):834-41
pubmed: 24475844
Cancer. 2004 Aug 1;101(3):613-9
pubmed: 15274075
J Chiropr Med. 2016 Jun;15(2):155-63
pubmed: 27330520
J Neurosurg. 2018 Sep 14;131(2):500-506
pubmed: 30215565
Br J Neurosurg. 1995;9(3):367-73
pubmed: 7546358
Radiology. 2015 Jun;275(3):803-9
pubmed: 25633504
Endocrinol Metab Clin North Am. 1992 Sep;21(3):669-92
pubmed: 1521518
J Neurol Surg B Skull Base. 2017 Jun;78(3):273-282
pubmed: 28603683
Ann Saudi Med. 2016 Sep-Oct;36(5):341-345
pubmed: 27710986
Hormones (Athens). 2018 Jun;17(2):261-267
pubmed: 29858852
World Neurosurg. 2019 Aug;128:e752-e759
pubmed: 31077893
AJNR Am J Neuroradiol. 2017 Nov;38(11):2067-2072
pubmed: 28912278
Neuroradiology. 2016 May;58(5):433-41
pubmed: 26873830
Neurosurgery. 1993 Oct;33(4):610-7; discussion 617-8
pubmed: 8232800
J Neurosurg. 2014 May;120(5):1086-94
pubmed: 24527820
Lancet Neurol. 2017 Jul;16(7):564-570
pubmed: 28653648
AJNR Am J Neuroradiol. 2021 Aug;42(8):1421-1428
pubmed: 34117017
J Neurosurg. 2018 Aug 10;131(2):549-554
pubmed: 30095338
Biomed Res Int. 2016;2016:3918292
pubmed: 27652261
J Clin Endocrinol Metab. 2008 Oct;93(10):3717-26
pubmed: 18682516
Best Pract Res Clin Endocrinol Metab. 2009 Oct;23(5):667-75
pubmed: 19945030
Clin Endocrinol (Oxf). 2018 Sep;89(3):354-359
pubmed: 29920729
Invest Radiol. 2015 Jul;50(7):470-2
pubmed: 25756685
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571